Key facts
- Notable investors include GL Ventures, IDG Capital, Oriental Fortune Capital, China Merchants Venture Capital, Hebei Coastal Industry Investment Fund — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Vitalgen
- ·The full record, as it builds
Funding rounds
No funding rounds for Vitalgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vitalgen
Developer of gene therapy and biopharmaceutical innovation intended for global pharmaceutical companies, healthcare providers, and research institutions. The company is committed to transforming cutting-edge gene delivery and gene editing technologies, thereby enabling clients to accelerate therapeutic development, expand treatment accessibility, and deliver life-changing interventions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- vitalgen.com/
- Ownership
- Privately Held (backing)
Vitalgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vitalgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vitalgen in its N-PORT filings yet. We sweep new filings monthly.